Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides
Macimorelin structure

Macimorelin

Growth Hormone
Approved Research
90%
Low Risk
1/5

Dosing Protocol

Typical Dose 0.5 mg
Range 0.5 - 0.5 mg

Pharmacokinetics

Half-Life 4.0 hrs
Onset 30 min
Peak 1.0 hrs
Duration 6.0 hrs
Bioavailability 70%
Primary Route Oral

Administration

Routes Oral
Syringe Type Oral
Timing Fasted

Special Instructions

FDA approved for GH deficiency DIAGNOSIS only. Single dose test - GH measured 30, 45, 60, and 90 minutes post-dose. Not for repeated therapeutic use.